Editorial on “Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era”

During the immunotherapy era, cytoreductive nephrectomy (CN) has been the standard of care in the treatment of metastatic renal cell carcinoma (mRCC). This practice was supported by randomized trials and large, retrospective studies (1-3). However, the low response rate and high toxicity associated with high-dose regimens as well as the wide-ranging spectrum of response to treatment have clearly demonstrated the need for further research and for standardized determination of patient and disease characteristics to predict clinical outcomes.